Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07417631 · ClinicalTrials.gov registry record
Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.
A clinical trial of Type 2 Diabetes, sponsored by Brigham and Women's Hospital.
- Active
- Registry status
- 30,000
- Enrollment target
- 1
- Study location
NCT07417631: Active study of Type 2 Diabetes, sponsored by Brigham and Women's Hospital.
NCT07417631 is a study of Type 2 Diabetes that is active but no longer recruiting, run by Brigham and Women's Hospital. The registered enrollment target is 30,000 participants, above the 3,832-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (683% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07417631, a study of Type 2 Diabetes, is active but no longer recruiting, sponsored by Brigham and Women's Hospital.
- ACTIVE NOT RECRUITING
- Registry status
- 30,000 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such studies.
Primary Outcome
The primary outcome is the time from cohort entry to the first occurrence of any component of the composite endpoint: myocardial infarction, stroke, or all-cause mortality in patients with T2DM with and without previous CVD, comparing dulaglutide versus sitagliptin, when following the eligibility criteria of the REWIND trial.
Conditions Studied
Interventions
- DRUG Sitagliptin
- DRUG Dulaglutide
Study Locations (1)
Massachusetts
- Brigham and Women's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30,000 participants |
| Start Date | 2026-02-03 |
| Est. Completion | 2026-03 |
What the registry record for NCT07417631 still lists
NCT07417631 is an observational study that tracks outcomes without assigning an intervention. Its 30,000 participants enrollment target places it among the larger protocols in the corpus, above the 3,832-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (683% higher).
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Sitagliptin is the first listed.
NCT07417631 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT07417631 about?
NCT07417631 is a clinical study titled "Emulation of the REWIND Cardiovascular Outcomes Trial in Healthcare Claims Data.". Investigators are building an empirical evidence base for real world data through large-scale emulation of randomized controlled trials. The investigators' goal is to understand for what types of clinical questions real world data analyses can be conducted with confidence and how to implement such s...
What is the current status of trial NCT07417631?
This trial is currently active not recruiting. The enrollment target is 30,000 participants. The study started on 2026-02-03. Estimated completion is 2026-03.
What conditions does trial NCT07417631 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT07417631?
The interventions under investigation include: Sitagliptin (DRUG), Dulaglutide (DRUG).
Who is sponsoring clinical trial NCT07417631?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07417631 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07417631's enrollment target sits among peer trials
30,000 6th of 327 higher than 322 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhancing Telemedicine for T2D
RECRUITING · NA
-
Sleep and Glycemic Control in Type 2 Diabetes Adolescents
RECRUITING · NA
-
Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
RECRUITING · NA
-
Ultrasound Effects on Glycemic Control in T2DM
RECRUITING · NA
-
Mechanism of SGLT2 Inhibition in the Kidney
RECRUITING · Phase 4
-
Acute and Chronic Effects of Oral Ketones in Subjects With HFrEF and Diabetes
RECRUITING · Early Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00684580 · 30,000 participants
Protocol For Collecting Data On Patients With Childhood Cancer
- NCT03053193 · 30,000 participants
MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
- NCT03689595 · 30,000 participants
Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)
- NCT04834869 · 30,000 participants
COVID-19 Vaccines Safety Tracking (CoVaST)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI